Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension

Kathryn N. Farrow*, Robin H. Steinhorn

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

24 Scopus citations


Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.

Original languageEnglish (US)
Title of host publicationPhosphodiesterases as Drug Targets
EditorsSharron H. Francis, Miles D. Houslay, Marco Conti
Number of pages27
StatePublished - 2011

Publication series

NameHandbook of Experimental Pharmacology
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325


  • Bronchopulmonary dysplasia
  • Congenital diaphragmatic hernia
  • Nitric oxide
  • Persistent pulmonary hypertension of the newborn
  • Phosphodiesterase
  • Prostacyclin
  • cAMP
  • cGMP

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension'. Together they form a unique fingerprint.

Cite this